Research groups | Participants | Analyte | Method | Main findings |
---|---|---|---|---|
Herbert et al73 | PD n=43, MSA n=23, controls n=30 | DJ-1 | ELISA |
|
Constantinescu et al78 | PD n=6, MSA n=13, PSP n=18, CBD n=6, HC n=18 | Urate | Enzymatic method on a modular system | No difference |
Wennstrom et al47 | PD n=38, PDD n=22, DLB n=33, AD n=46, HC n=52 | Neurosin | ELISA |
|
Goldstein et al82 | PD n=34, MSA n=54, PAF n=20, HC n=38 | Dihydroxyphenylatic acid (DOPAC) | Batch alumina extraction followed by liquid chromatography with electrochemical detection |
|
Salvesen et al72 | PD n=30, DLB n=17, MSA n=14, PSP n=19 | DJ-1 | ELISA | No difference among groups |
Maetzler et al77 | PD n=55, PDD n=20, DLB n=20, controls n=76 | Uric acid | ADVIA analyser+photometric methods | Increase in PD vs DLB |
Shi et al22 | Discovery cohort: PD n=126, MSA n=32 AD n=50, controls n=137 Validation cohort: PD n=83 | DJ-1 Fractalkine | Bead-based multi-analyte assay (Luminex) |
|
LeWitt et al81 | PD n=217 (samples collected ×2 occasions) HC n=26 | Homovallinic acid/xanthine ratio | Gas chromatography-mass spectrometry |
|
Wang et al79 | PD n=86, MSA n=20, AD n=38 HC n=91 | Complement C3/factor H (FH) | Bead-based multi-analyte assay (Luminex) |
|
Maetzler et al80 | PD n=38, PDD n=20, DLB n=21 m, controls n=23 | Neprilysin | Fluorometric assay | Decrease in DLB+PDD vs PD+ controls |
Hong et al52 | PD n=117, AD n=50, HC n=132 | DJ-1 | Bead-based multi-analyte assay (Luminex) |
|
AD, Alzheimer's disease; CBD, corticobasal degeneration; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; HC, healthy controls; MSA, multiple system atrophy; PAF, pure autonomic failure; PD, Parkinson's disease; PDD, Parkinson's disease dementia; PSP, progressive supranuclear palsy.